Colazal: The Fight Against Ulcerative Colitis

Each year, senior adults, especially baby boomers, complain of pain and discomfort associated with bowel movements and the colon. Of these senior adults, many will seek out medical treatment to not only relieve symptoms but also remedy a condition known as ulcerative colitis. In an effort to provide an efficient remedy, the healthcare professional will commonly approach the ulcerative colitis treatment plan using the FDA approved drug known as Colazal. Understanding the use, dosing and side effects of Colazal will provide senior adults, suffering from colon pain, with a better understanding in the overall ulcerative colitis treatment plan

Colazal, distributed by Salix Pharmaceuticals, Inc., is an FDA approved drug used to treat the cause, origin and symptoms of ulcerative colitis in senior adults. Colazal lends its success in the improvement of ulcerative colitis through the relief of abdominal pain and rectal bleeding. In fact, Colazal, in the use of nausea and vomiting, has become so successful that many geriatric specialists now prescribe Colazal as a common remedy for gastrointestinal discomfort in the aging population.

Dosing of Colazal, in the treatment of gastrointestinal bleeding and rectal pain associated with ulcerative colitis, is available as a 750 milligram tablet. Under standard ulcerative colitis treatment the geriatric specialists will, as a general rule, prescribe these 750 milligram tablets, three times per day with treatment extending from eight to 12 weeks.

As with any FDA approved treatment, Colazal, in the treatment of ulcerative colitis in senior adults, may pose side effects and health risks. While most senior adult patients report pain and symptoms are significantly are reduced, many senior adults will report an increase in additional Colazal treatment related symptoms such as nausea, vomiting and slight headache pain. As a Category B, FDA approved drug, Colazal has been shown to produce no adverse reaction in women who are undergoing fertility treatments, women who are pregnant, nor health risk to a fetus. However, before using Colazal, the healthcare professional should first determine the pregnancy status of the senior adult patient so as to ensure close monitoring of any other adverse reactions.

As with any form of gastrointestinal treatment, senior adults should discuss the options and side effects in using Colazal in the treatment of ulcerative colitis, in an effort to control and foresee any potential reactions which may present as a result of co morbid conditions such as colon or prostate cancer.

When suffering from abdominal pain and rectal bleeding, consult a healthcare professional regarding testing to rule out ulcerative colitis. When positively diagnosed with ulcerative colitis, discuss the use of Colazal in the treatment program commonly recommended by the geriatric specialist of gastroenterology.